H IV -1 infection typically involves a long clinical latency stage during which CD4 counts decline slowly. For the later p a rt of the clinical latency stage it was found recently th a t this is a highly dynam ic phase characterized by rap id tu rnover rates. Clinical latency can therefore be considered as a quasi-equilibrium state in w hich CD4 and H IV -1 turnover are in alm ost perfect balance. H ere we consider this quasi equilibrium to be the stable steady state of a simple ho st-p arasite m odel in which the parasite (H IV -1) level is determ ined by the availability of infectable hosts (activated C D 4+ T cells). Such models adequately account for the clinical d a ta on the evolution of drug resistant m utants appearing after the adm in istratio n of a n ti-H IV drugs. T h e m odel suggests a novel therapeutic approach for A ID S: reducing the CD4 count slightly will strongly reduce the H IV load. C om bining this anti-C D 4 treatm ent with conventional a n ti-H IV therapy would prevent the outgrow th of drug resistant m utants. An alternative answ er is the 'ecological view ' stating th at the H IV -1 infection is lim ited by the availability of target cells (M cL ean et al. 1991; M cL ean & Nowak 1992; Frost & M cL ean 1994; M cL ean & Frost 1995; Perelson et al. 1993; Essunger & Perelson 1994; Coffin 1995£; Phillips 1996) . A ccording to this view the im m une response m ay be im p o rtan t, but is assum ed to rem ain fairly constant over the time course of the clini cal experim ents discussed here. T he d a ta supporting the ecological view involve perturbations of the clinical latency equilibrium by therapeutic intervention. In creasing the activation and the num bers of C D 4+ T cells by IL2 treatm en t increases both the viral RNA load and the CD4 cell count (Kovacs et al. 1995). Im m unization of HIV -1 infected individuals with influenza vaccine has a side effect of increasing C D 4+
S U M M A R Y
H IV -1 infection typically involves a long clinical latency stage during which CD4 counts decline slowly. For the later p a rt of the clinical latency stage it was found recently th a t this is a highly dynam ic phase characterized by rap id tu rnover rates. Clinical latency can therefore be considered as a quasi-equilibrium state in w hich CD4 and H IV -1 turnover are in alm ost perfect balance. H ere we consider this quasi equilibrium to be the stable steady state of a simple ho st-p arasite m odel in which the parasite (H IV -1) level is determ ined by the availability of infectable hosts (activated C D 4+ T cells). Such models adequately account for the clinical d a ta on the evolution of drug resistant m utants appearing after the adm in istratio n of a n ti-H IV drugs. T h e m odel suggests a novel therapeutic approach for A ID S: reducing the CD4 count slightly will strongly reduce the H IV load. C om bining this anti-C D 4 treatm ent with conventional a n ti-H IV therapy would prevent the outgrow th of drug resistant m utants.
IN T R O D U C T IO N
R ecent clinical d a ta on the decrease of the H IV -1 plasm a level, and the increase of the C D 4 T cell count, following the treatm en t w ith anti-viral drugs have been analysed m athem atically to suggest th at clinical H IV -1 latency involves high turnover rates of both the virus and the C D 4+ T cells (Ho et al. 1995; W ei et 1995; Now ak et al. 1995 a; Perelson et al. 1996) . Given th at the H IV -1 clinical latency stage typically lasts for several years (Fauci 1993; Levy 1993; Weiss 1993) , these findings raise the question how virus levels are kept u n d er control for so long (Coffin 1995 a) . O ne answ er to this question is the 'im m unological v iew ' stating th at the H IV -1 infection is controlled by the im m une system. T h ere is good em pirical evidence for both a h um oral (Fauci 1993; Levy 1993; Weiss 1993 ) and a cellular (Phillips et al. 1991; Now ak 1995 Now ak K lein et al. 1995 Now ak & B angham 1996; Levy et al. 1996) im m une response.
An alternative answ er is the 'ecological view ' stating th at the H IV -1 infection is lim ited by the availability of target cells (M cL ean et al. 1991; M cL ean & Nowak 1992; Frost & M cL ean 1994; M cL ean & Frost 1995; Perelson et al. 1993; Essunger & Perelson 1994; Coffin 1995£; Phillips 1996) . A ccording to this view the im m une response m ay be im p o rtan t, but is assum ed to rem ain fairly constant over the time course of the clini cal experim ents discussed here. T he d a ta supporting the ecological view involve perturbations of the clinical latency equilibrium by therapeutic intervention. In creasing the activation and the num bers of C D 4+ T cells by IL2 treatm en t increases both the viral RNA load and the CD4 cell count (Kovacs et al. 1995) . Im m unization of HIV -1 infected individuals with influenza vaccine has a side effect of increasing C D 4+ Corey 1995) can be beneficial by increasing CD4 T cell counts, and, in one instance (W eber & G alpin 1995) , decreasing the viral load. N ote however, th at cyclo sporin also has direct anti-viral effects Steinkasserer et al. 1995) .
T he ecological and im m unological views are not m utually exclusive. First, during disease progression the infection could evolve from im m unological to ecological control. This is supported by the IL2 treatm ents w here the adverse effects on the viral load are most pronounced in late stage patients (Kovacs et al. 1995) . Second, even if the control of the virus at the clinical latency equilibrium is dom inated by the im m une response (Nowak & B angham 1966) , p er turb atio n of this equilibrium by therapeutic in ter ventions can give rises to transients during which the fast expansion of target cells dom inates over a m ore slowly changing im m une response. T hus, w henever the im m une response adapts sufficiently slow to changes in the virus load, the virus is transiently limited by the available target cells.
T he recent clinical trials with anti-viral drugs like protease inhibitors (Ho et al. 1995 Figure 1 . Anti-viral treatment for math-AIDS and for a representative example (i.e. Case number 11) from a group of 20 asymptomatic or mildly symptomatic AIDS patients treated with the RT-inhibitor lamivudine (Schuurman et al. 1995) . The initial CD4 T cell count and viral RNA load of Case number 11 were 215 cells per pi, and 3.64 x 104 copies per ml, respectively. Assuming this to be an equilibrium we obtain the same initial condition in our model by setting c = 1136 and y = 2.2 x 1CT6 T cells per scaled virus particle per day. We mimic the lamivudine treatment by admin istering an RT-inhibitor at day zero, i.e. we set the effective drug concentration D = 10. Thus the RT fitness of the wildtype decreases 11-fold (see equation (la)), whereas that of the drug-resistant mutant decreases marginally (i.e. by 2%, see equation ( , and the RNA loads of the wild type (dashed line with diamonds) and the drug-resistant mutant (dash-dotted line with squares). We assume that the drug-resistant mutant is present at low concentration, i.e. 7j(0) = 0.1 cell per ml, before the onset of treatment (Najera etal. 1995) . The model and the data agree closely on the slope with which the total RNA load decreases. In the model and in the data we find that the drug-resistant mutant has completely replaced the wild type after about 2 weeks. In the data we a find a rebound of the wild type after about 3 weeks. 1996) . Within the ecological view, the wild type rebound is explained by the recovery of the CD4 count. This provides more 'food' for the virus and thus compensates for the anti viral treatment. We conclude that our simple host-parasite model provides a reasonable fit for both our own clinical data (i.e. Case number 11), and for a compilation of several independent clinical data sets (Coffin 1995(2) . Parameters: .66 x 105 copies per ml, respectively. We obtain the same initial condition in our model by setting c = 8046 and y = 3.6 x 10-7 T cells per scaled virus particle per day. Case number 20 is more typical for the lamivudine data because the total CD4 increase is rather limited (i.e. about 30%). Additionally, the data show that before the onset of treatment 2 % of viral quasi species is drug-resistant. We therefore increase the mutant's initial density by setting Tr = 1. Thus we obtain an initial viral load of the mutant that is similar to that of the data (cf. panel c).
All other parameters of the model are kept the same as those in figure 1. The time plots of the CD4 T cell count per pi in the data (a) and the model (b) agree reasonably. The total CD4 increase in the model is indeed much smaller than that in figure 1 (note difference in scale of the vertical axis). Thus the mild increase of the CD4 counts in the lamivudine data (as compared with the protease data (Ho et al. 1995; Wei et al. 1995) ) can partly be explained by the higher initial frequencies of the drug-resistant mutants (lamivudineresistant mutants require only one point mutation (Schuurman et al. 1995) ). The time plots of the viral RNA load per ml of the data (c) and the model (d) are in qualitative agreement. The total decrease in the viral load in the data is however ten-fold larger than that in the model. Given the simplicity of our model we however consider this fit between model and data to be reasonable. 
M O D E L
In response to an a n ti-H IV therapy the virus quasi species typically evolves several drug-resistant m utants (Larder et al. 1989 (Larder et al. , 1991 
= <x-dT Ti -y T l {Jw Vw+ f r Vr), (4) at
where cr is the source o f newborn cells from the thymus, dT is the death rate of uninfected CD4 cells, and the y term describes the infection of 7^ cells by either wild type or by resistant virus. As the model combines resting and cycling T cells the lifetime of the T cells is set to an interm ediate length of 100 d (cf. M cLean & M itchie 1995), i.e. we set dT = 0.01 per day. Thus we obtain a norm al CD4 count of a 1000 cells per pi when we set cr = 10 cells per pi per day (which is in full agreem ent with recent estimates (Ho al. 1995; Wei et al. 1995) ).
R E S U L T S
We first com pare the behaviour of our model with our d ata on the response of the plasm a HIV -1 RN A load and the CD4 T cell count to treatm ent with lam ivudine ( evolves, m utants with both a high drug-resistance and with a R T fitness com parable to that of the wild type, drug therapies like this tend to be unsuccessful. By considering the pre-treatm ent situation more closely we now develop our im muno-suppressive therapy for m ath-A ID S. Because the m utant strain is typically small in the pre-treatm ent situation we can ignore equation (3). Thus, the model simplifies into a simple epidemic of one parasite Tw ijnfecting a host population 7^ with a reproduction ratio of R = c y T J d j.In epidemiology it is well known that a parasite requires a critical density of infectable hosts for its survival (K erm ack & M cK endrick 1927), i.e. in our case the virus will only survive when ^ 1. At the clinical latency equilibrium R = 1 because the CD4 level, i.e. 7^ = d , / (cy ) (see equation 2), is exactly at the threshold.
Thus, bringing the target cell level below th at of the clinical latency quasi-equilibrium should eradicate the virus in our model. This means th at a therapeutic approach for m ath-A ID S is the adm inistration of an im muno-suppressive drug reducing CD 4+ T cell ac tivation or the CD4 T cell counts (e.g. cyclosporin, or an anti-C D 4 antibody (Wofsy & C arteron 1990) ). In our simple m odel we im plem ent the latter by adding to equation (4) 
i f = < r -d T Ti -y T i { f ,V w + f r V,) -a T" (5) dt
where a is the rate at which CD4 T cells are removed by the drug. Sim ilar results would be obtained if we were to reduce the source of target cells cr as a model for blocking CD4 T cell activation (not shown). In the absence of the virus the equilibrium of equation (5) is at
T4 -cr/(dT + < x ) . H ence we find the critical anti-
CD4 treatm ent at which
infected equilibrium equal to the clinical latency equilibrium , i.e. by setting ) = dfcy). Solving for a, we obtain a = / djfor the critical anti-C D 4 treatm ent beyond which the virus is eradicated. O ne can easily check from our model th at this rate a corresponds to the equilibrium rate at which a target cell is expected to be infected by virus. Thus, by suppressing as m any T cells as the virus is infecting, the critical anti-C D 4 treatm ent yields a CD4 T count th at is identical to th at of the clinical latency equilibrium . Because the virus is infecting large num bers of T cells per day (Ho et al. 1995; Perelson al. 1996) , the anti-C D 4 treatm ent has to be strong. T he surprising m athem atical result is however that, despite the strong treatm ent, the GD4 T cell count of the m ath-A ID S patient need only by reduced m arginally. This is illustrated in figure 3 where we introduce the anti-C D 4 therapy into the clinical latency state of the m ath-A ID S case depicted in figure 1. T he effects of a m inim al anti-C D 4 treatm ent is studied by setting <x = 0.041 in figure 3 a. W e observe th at H IV R N A levels decline steadily, th at CD4 levels decline about 25% until day 15, and then recover to about 10% below baseline. T he GD4 recovery is caused by the reduction of the virus load. T he crucial new phenom enon is th at the virus never rebounds (as long as the anti-C D 4 therapy is continued). Slowly increasing the dosage of the anti-C D 4 therapy until one observes a rapid drop of the HIV -1 RN A load, allows one to determ ine in vivo the critical anti-C D 4 treatm ent. In figure 3 b we linearly increase the anti-C D 4 treatm ent from a = 0 at day zero to a -0/04 then on the treatm ent rem ains at = 0.041.
O u r im m uno-suppressive therapy should have a highly synergistic effect on any of the conventional anti-viral drugs. In Figure 3c we do a com bination of the anti-C D 4 and the an ti-H IV treatm ent in the m ath-AID S patient depicted in figure 1. Im portantly, the drug-resistant m utants do not appear (cf. figure 1) , and . The treatment cures m ath-A ID S: the total virus load declines monotonically, no m utant ever appears, and CD4 levels first decrease (by approximately 25 %) and then increase to approximately 10% below baseline. This anti-CD4 therapy thus suffices for markedly reducing the virus load; it is however associated with some reduction of the CD4 T cell count. To clinically assess the critical anti-CD4 treatment, we gradually build up the anti-CD4 therapy in panel ( ). At day zero a = 0, it increases linearly to a = 0.041 at day 41, then the treatment remains at a = 0.041. One can thus increase the anti-CD4 dosage, monitoring the CD4 counts and the HIV-1 RNA loads, until one sees a rapid drop of the HIV-1 RNA load. In panel (c) we combine the anti-H IV therapy of figure 1 (i.e. D = 10) with the critical anti-CD4 therapy of Figure 3 a (i.e. a = 0.041). The virus now drops much faster,, the CD4 levels never decrease more than 10%, and the drug-resistant m utant never appears. (The decrease of the CD4 count is largely caused by the disappearance of the C D 4 levels never decrease more than 10% . Thus, by careful tuning the anti-C D 4 therapy one can prevent the outgrowth of the drug-resistant mutants while keeping the C D4 count at reasonable levels. (1996)). As the drug-resistant m utants make the anti-H IV therapy quite unsuccessful, the possibility that the appearance o f drug-resistant variants can be prevented by an anti-C D 4 treatm ent is not only extrem ely controversial but also extrem ely intriguing.
C A V E A T S

Decreasing activated C D 4+ T cells is
T he main controversy remains our assumption that the virus can be target-cell-lim ited. N ot denying that the infected CD4 cells.) Thus one can prevent the evolution of drug-resistant mutants by preventing the increase of the CD4 count evoked by the anti-HIV treatment.
the im m une response may dom inate in the control of the virus in the clinical latency equilibrium , we would argue that several clinical data sets do support the notion that the virus becomes target-cell-lim ited when the clinical latency equilibrium is perturbed by therapeutic intervention. Perturbations of the clinical latency equilibrium with anti-viral drugs inhibiting HIV-1 R T or HIV-1 protease (Ho al. 1995; Wei et al. 1995; Nowak et a l . 1995a; Perelson et 1996) , with the im m uno-stim ulatory drug IL2 (Kovacs 1995), with influenza vaccination (Staprans et al. 1995) , and with immuno-suppressive drugs like cyclosporin or prednisolone (Andrieu et al. 1988 (Andrieu et al. , 1995 Fauci 1993; Schwarz et al. 1993; W eber & G alpin 1995; Corey 1995) , are all reported to affect target cell num bers (as measured by the CD4 cell count). T he fact that im m uno-stim ulation by either influenza vaccination (Staprans et al. 1995; O 'Brien al. 1995) or IL2 treatm ent tends to increase the viral load (Kovacs al. 1995) , and that im m uno-suppression can have beneficial effects (Andrieu et al. 1988 (Andrieu et al. , 1995 Fauci 1993; Schwarz et al. 1993; W eber & G alpin 1995; Corey 1995) , is most readily explained by target-celllim itation, i.e. by the ecological view.
T he issue is com plicated however because the ecological and im m unological views are not m utually exclusive, e.g. during disease progression the infection could evolve from im munological to ecological control. If this is so, anti-C D 4 treatm ent will be detrim ental during the early stages and beneficial during the late stages of disease. F urtherm ore, in models where the specific im m une response changes rath er slowly (e.g. because of im m une m em ory effects) the more rapid ecological effects dom inate transiently such that anti-CD4 treatm ent is transiently beneficial (m anuscript in preparation).
T he fact th at in some of the d ata on the im m uno suppressive therapies the CD4 count increases but the viral load hardly responds (Andrieu et al. 1988 (Andrieu et al. , 1995 Corey 1995) , is in agreem ent with a more detailed model of ours in which H IV -1 only infects activated T cells (De Jo n g et al. 1996; Stilianakis et al. 1996) . The same model also allows us to model disease progression as the hyperactivation of the im m une system (Fauci 1993) . T hus, m odelling progression by increasing the T cell activation rate, our ecological model accounts for the conventional increase in the viral load acco m panied by a degree of the CD4 levels (De Jo n g al.
1996; Stilianakis et al. 1996).
T he m ain problem to expect with an anti-C D 4 therapy is that the virus will not really be eradicated. HIV -1 can persist in long-lived cells (e.g. wild-type HIV-1 DNA remains present for m onths after anti-H IV therapy (Wei et al. 1995; C. A. B. Boucher, unpublished d ata) . Thus one expects the virus to re appear from such 'reservoirs' as soon as the anti-C D 4 treatm ent is interrupted. Clinical d ata (W eber & G alpin 1995) from an A ID S patient treated with cyclosporin are in agreem ent with this. O ver a 30-week-period the p atien t's CD4 counts fell from 960 to 530, and the viral load dropped 84% . W hen the cyclosporin treatm ent was interrupted, viral load and CD4 counts rose back to baseline. Sim ilar d ata have hitherto been interpreted in the light of chronic hyperactivation (Ascher & Sheppard 1988; Fauci 1993) or auto-im m une effects (H abeshaw al. 1992; Weiss 1993; Andrieu et al. 1995) involved in HIV-1 infection.
Given the results presented here we prefer to interpret these d ata as support for the ecological view, and as its n atural consequence, as support for an anti-CD4 therapy. M oreover, an anti-C D 4 therapy killing C D 4+ cells should be m uch more effective than cyclosporin because killing CD 4+ cells should also affect virus hiding in the resting T cell (Bukrinsky et al. 1991; Zack et al. 1991) and m acrophage reservoirs (Weiss 1993) . Finally, we stress again th at our hypothesis depends strongly on the ecological view th at we have adopted here, and th at anti-C D 4 treatm ent should be detrim ental if this view turns out to be wrong. As a critical test distinguishing the ecological from the im m unological view one should begin to design experim ents m easuring the effects of anti-C D 4 treatm ents in anim al models.
